Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Univec, Inc. (OTCMKTS:UNVC) Sees Significant Drop in Short Interest
https://www.etfdailynews.com/2022/05/26/univec-inc-otcmktsunvc-sees-significant-drop-in-short-interest/
(OTCMKTS:UNVC)
Ford Unleashes Heavy Artillery Against Tesla and GM
https://www.thestreet.com/technology/ford-wants-to-rattle-rivals
Ford vs. Ferrari vs. Corvette: Mustang GT3 racer takes on the world (F)
https://www.detroitnews.com/story/business/autos/2022/01/28/ford-vs-ferrari-vs-corvette-mustang-gt-3-racer/9251143002/?gnt-cfr=1
Ford Motor Company (F)
Univec Inc (PK) (UNVC) ++16.58% ^
Volume: 1,190,548 @01/14/22
I love that stock
Univec Inc (UNVC)
Ford Stock Leaps Tesla Cybertruck Delay Report, Deutsche Bank Price Target Boost
https://www.thestreet.com/markets/ford-stock-gains-on-tesla-cybertruck-delay-report-deutsche-boost
Tesla, Inc. (TSLA)
Things appear to be going from good to great for Ford (NYSE:F) stock.
https://investorplace.com/2022/01/f-stock-buy-into-the-transformation-of-ford-as-an-ev-maker/
Ford Motor Company (F)
Tonix Pharma next gen covid vaccine
Tonix Pharma, Kansas University Join Forces To Work On Next-Gen mRNA-Based COVID-19 Vaccine
https://finance.yahoo.com/news/tonix-pharma-kansas-university-join-141207647.html
Tonix Pharmaceuticals Holding Corp (TNXP)
America's best-selling car is Ford
https://www.msn.com/en-us/money/companies/americas-best-selling-car-is-the-ford-f-150-not-gm-or-toyota/ar-AASstBH
Ford Files 8-k Current Report Filing (8-k)
https://ih.advfn.com/stock-market/NYSE/ford-motor-F/stock-news/86948781/current-report-filing-8-k#EXHIBIT99DECEMBER2021SAL_HTM
Ford Motor Company (F)
"We want to build them at the Rouge" factory near Ford's headquarters in Dearborn, Michigan.
Farley said F-150 Lightning orders were capped at 200,000: "We had to stop taking reservations because we had so many."
https://www.reuters.com/business/autos-transportation/ford-caps-f-150-lightning-orders-200000-ceo-farley-2021-12-09/
Ford Motor Company, which has a market valuation of $82.81 billion, is expected to release its quarterly earnings report Feb 02, 2022 – Feb 07, 2022. The company stock has a Forward Dividend ratio of 0.40, while the dividend yield is 2.00%. It is understandable that investor optimism is growing ahead of the company’s current quarter results. Analysts tracking F have forecast the quarterly EPS to grow by 0.27 per share this quarter, while the same analysts predict the annual EPS to hit $1.6 for the year 2021 and up to $1.91 for 2022. In this case, analysts estimate an annual EPS growth of 290.20% for the year and 19.40% for the next year.
On average, analysts have forecast the company’s revenue for the quarter will hit $33.99 billion, with the likely lows of $29.77 billion and highs of $40.05 billion. Staying with the analyst view, there is a consensus estimate of $129.73 billion for the company’s annual revenue in 2021. Per this projection, the revenue is forecast to grow 11.90% above that which the company brought in 2021.
Ford Motor Company (F)
Tesla Inc. (NASDAQ:TSLA) has experienced a decrease in hedge fund sentiment in recent months. Tesla Inc. (NASDAQ:TSLA) was in 60 hedge funds' portfolios at the end of the second quarter of 2021. The all time high for this statistic is 68. Our calculations also showed that TSLA isn't among the 30 most popular stocks among hedge funds (click for Q2 rankings).
So, why do we pay attention to hedge fund sentiment before making any investment decisions? Our research has shown that hedge funds' small-cap stock picks managed to beat the market by double digits annually between 1999 and 2016, but the margin of outperformance has been declining in recent years. Nevertheless, we were still able to identify in advance a select group of hedge fund holdings that outperformed the S&P 500 ETFs by more than 79 percentage points since March 2017 (see the details here). We have been able to outperform the passive index funds by tracking the moves of corporate insiders and hedge funds, and we believe small investors can benefit a lot from reading hedge fund investor letters and 13F filings.
Tesla, Inc. (TSLA)
Ford Motor Company [F] Stock trading around $17.95 per share
Ford Motor Company [NYSE: F] stock went on an upward path that rose over 5.09% on Monday, amounting to a one-week price increase of more than 12.19%. The company report on October 28, 2021 that Qmerit Teams Up with Ford Motor Company for Electric Vehicle Home Charging Installations for Automaker’s Mustang Mach-E Customers.
Qmerit, a leader in electrification and green energy transformation, has teamed up with Ford Motor Company for home EV charger station installations for its currently available all-electric vehicles. Qmerit will provide Ford’s Mustang Mach-E customers with its Charge@Home services for installing and supporting EV charger stations at individual homes and multi-family residences.
Ford Strives for an All-Electric Future.
Over the last 12 months, F stock rose by 132.21%. The one-year Ford Motor Company stock forecast points to a potential downside of -7.36. The average equity rating for F stock is currently 2.40, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $69.53 billion, with 4.00 billion shares outstanding and 3.84 billion shares in the current float. Compared to the average trading volume of 66.38M shares, F stock reached a trading volume of 121142623 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Ford Motor Company [F]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for F shares is $16.72 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on F stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Credit Suisse have made an estimate for Ford Motor Company shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on October 20, 2021. While these analysts kept the previous recommendation, Barclays raised their target price from $15 to $17. The new note on the price target was released on June 22, 2021, representing the official price target for Ford Motor Company stock. Previously, the target price had yet another raise from $13 to $17, while RBC Capital Mkts kept a Outperform rating on F stock.
The Average True Range (ATR) for Ford Motor Company is set at 0.63, with the Price to Sales ratio for F stock in the period of the last 12 months amounting to 0.51. The Price to Book ratio for the last quarter was 1.96, with the Price to Cash per share for the same quarter was set at 11.99. Price to Free Cash Flow for F in the course of the last twelve months was 6.43 with Quick ratio for the last quarter at 1.00.
F Stock Performance Analysis:
Ford Motor Company [F] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.19. With this latest performance, F shares gained by 26.77% in over the last four-week period, additionally plugging by 57.32% over the last 6 months – not to mention a rise of 132.21% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for F stock in for the last two-week period is set at 75.44, with the RSI for the last a single of trading hit 78.19, and the three-weeks RSI is set at 72.64 for Ford Motor Company [F]. The present Moving Average for the last 50 days of trading for this stock 14.29, while it was recorded at 16.67 for the last single week of trading, and 13.28 for the last 200 days.
Insight into Ford Motor Company Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Ford Motor Company [F] shares currently have an operating margin of -3.60 and a Gross Margin at +10.00. Ford Motor Company’s Net Margin is presently recorded at -1.01.
Return on Total Capital for F is now -2.39, given the latest momentum, and Return on Invested Capital for the company is -0.92. Return on Equity for this stock declined to -4.00, with Return on Assets sitting at -0.49. When it comes to the capital structure of this company, Ford Motor Company [F] has a Total Debt to Total Equity ratio set at 531.11. Additionally, F Total Debt to Total Capital is recorded at 84.15, with Total Debt to Total Assets ending up at 60.99. Long-Term Debt to Equity for the company is recorded at 362.76, with the Long-Term Debt to Total Capital now at 57.48.
Reflecting on the efficiency of the workforce at the company, Ford Motor Company [F] managed to generate an average of -$6,876 per employee. Receivables Turnover for the company is 2.20 with a Total Asset Turnover recorded at a value of 0.48.Ford Motor Company’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.20.
F Stock EPS
With the latest financial reports released by the company, Ford Motor Company posted 0.34/share EPS, while the average EPS was predicted by analysts to be reported at -0.07/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 585.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for F. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Ford Motor Company go to 77.67%.
Ford Motor Company [F] Insider Position Details
There are presently around $37,371 million, or 54.20% of F stock, in the hands of institutional investors. The top three institutional holders of F stocks are: VANGUARD GROUP INC with ownership of 296,718,176, which is approximately 1.4% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 262,017,186 shares of the stock with an approximate value of $4.7 billion in F stocks shares; and STATE STREET CORP, currently with $2.97 billion in F stock with ownership of nearly 0.174% of the company’s market capitalization.
>> 7 Top Picks for the Post-Pandemic Economy <<
Positions in Ford Motor Company stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 743 institutional holders increased their position in Ford Motor Company [NYSE:F] by around 179,948,667 shares. Additionally, 495 investors decreased positions by around 216,349,357 shares, while 227 investors held positions by with 1,685,643,932 shares. The mentioned changes placed institutional holdings at 2,081,941,956 shares, according to the latest SEC report filing. F stock had 170 new institutional investments in for a total of 27,543,090 shares, while 100 institutional investors sold positions of 25,666,249 shares during the same period.
F, F stock, Ford Motor Company, NYSE:F
Ford Motor Company (F)
PRESS RELEASE: Leaders in Healthcare Industry Join Forces to Address Mental Health and Substance Use Disorder
The color is green
Univec Inc (UNVC)
0.0770 +0.0017 (+2.26%) 11/02/21 [OTC US]
https://apnews.com/press-release/newswire/business-health-mental-health-anxiety-sleep-disorders-8357f1ba8ecb19faf52051cca263ff08
BALTIMORE - November 2, 2021 - ( Newswire.com )
Dr. David Dalton, CEO of UNIVEC, Inc., and Patrick Kelly, President of bioRemedies MD, LLC, today announced a breakthrough partnership to offer safe adjunct therapies for pain, anxiety, and sleep disorders. bioRemedies MD’s proprietary cannabinoid-based products will be used by UNIVEC, Inc. in clinical behavioral health settings for out-patient treatment.
bioRemedies MD’s scientifically formulated cannabinoid products are unlike anything on the market today. Through the use of FDA and pharmaceutical processes, technology, and standards, bioRemedies MD has been able to ensure high-quality, reproducible, and targeted formulations. Their proprietary nanotechnology delivers cannabinoids efficiently and effectively, a requirement for academic research and healthcare target markets, and allows their commercial products to compete on quality and cost. UNIVEC, Inc. will make private label and bioRemedies MD products available through several distribution channels throughout the U.S. market, including recently acquired community-based outpatient mental health centers.
https://apnews.com/press-release/newswire/business-health-mental-health-anxiety-sleep-disorders-8357f1ba8ecb19faf52051cca263ff08
Click to copy
Related topics
Business
Health
Newswire
Mental health
Anxiety
Sleep disorders
PRESS RELEASE: Paid content from Newswire
Leaders in Healthcare Industry Join Forces to Address Mental Health and Substance Use Disorder
today
BALTIMORE - November 2, 2021 - ( Newswire.com )
Dr. David Dalton, CEO of UNIVEC, Inc., and Patrick Kelly, President of bioRemedies MD, LLC, today announced a breakthrough partnership to offer safe adjunct therapies for pain, anxiety, and sleep disorders. bioRemedies MD’s proprietary cannabinoid-based products will be used by UNIVEC, Inc. in clinical behavioral health settings for out-patient treatment.
bioRemedies MD’s scientifically formulated cannabinoid products are unlike anything on the market today. Through the use of FDA and pharmaceutical processes, technology, and standards, bioRemedies MD has been able to ensure high-quality, reproducible, and targeted formulations. Their proprietary nanotechnology delivers cannabinoids efficiently and effectively, a requirement for academic research and healthcare target markets, and allows their commercial products to compete on quality and cost. UNIVEC, Inc. will make private label and bioRemedies MD products available through several distribution channels throughout the U.S. market, including recently acquired community-based outpatient mental health centers.
ADVERTISEMENT
“I recently announced the beginning of Univec’s business plan for ‘Wraparound Services’ in Maryland for the mental health and substance use disorder,” said Dr. David Dalton, CEO of Univec, Inc. “Aligning our work with bioRemedies MD is consistent with being in the forefront of delivering targeted care using custom-blend multi cannabinoid adjunct therapies.”
UNIVEC, Inc. is working to change the way healthcare is delivered in the United States. The company works with several community-based outpatient mental health centers to treat behavioral health. bioRemedies MD complements UNIVEC, Inc. principles—treating the patient as a whole and applying “total wraparound” support for patients, families, and caregivers.
Patrick Kelly, President of bioRemedies MD, LLC, remarked, “The time is now to bring these products to the community, weary from substance use disorders and barriers to mental health treatment. Our partnership with UNIVEC, Inc. meets people where they are to help those suffering from pain, opioid misuse, anxiety, and sleep disorders.”
About bioRemedies MD, LLC
bioRemedies MD specializes in cannabinoid-complementary and -integrative products. Their products have been in research and development at the company’s University of Maryland BioPark lab since industrial hemp research was legitimized 2016.
About UNIVEC Inc.
Univec Inc. is an organization targeted for change in the healthcare delivery system specializing in mental health and substance misuse.
Media Contact for bioRemedies MD, LLC Patrick Kelly pat@bioremmd.com.
Media Contact for UNIVEC, Inc. Dr. David Dalton info@univecconglomerate.com
Univec Inc (UNVC)
Leaders in Health Industry Join Forces to Address Mental Health and Substance Use
Disorder
Number of shares in the Public Float2: 221,867,522 as of date: 09/30/2021
Total number of shareholders of record: 106 as of date: 09/30/2021
Leaders in Health Industry Join Forces to Address Mental Health and Substance Use
Disorder
UNIVEC, Inc. and bioRemedies MD Align to Introduce products offering safe alternative to
pain, anxiety and sleep disorders
Baltimore, MD (October 28, 2021) – Dr. David Dalton, CEO of UNIVEC, Inc. (OTC Markets:(UNVC)
and Patrick Kelly, President of bioRemedies MD, LLC announced a breakthrough partnership to
offer safe adjunct therapies for pain, anxiety and sleep disorders in the behavioral health
setting.
Through a variety of proprietary formulated cannabinoid-based products developed by
bioRemedies MD, Univec, Inc. is prepared to begin using these products in clinical behavioral
health settings for out-patient treatment. bioRemedies MD specializes in Cannabinoid
complementary and integrative products that have been in research and development at the
University of Maryland Baltimore BioPark since 2016 after industrial hemp research was
legitimized.
bioRemedies MD develops scientifically formulated cannabinoid products using FDA and
Pharmaceutical processes, technology, and standards to ensure high quality, reproducible, and
targeted formulations unlike anything in the market today. Their proprietary nanotechnology
delivers cannabinoids efficiently and effectively, which is required for academic research and
healthcare target markets and allows our commercial products to compete on quality and cost.
Univec, Inc. (OTC Markets:(UNVC) is an organization with a mission to change the way
healthcare is delivered in America. Having recently announced the acquisition of several
community based out-patient mental health centers to treat behavioral health. bioRemedies
MD compliments Univec, Inc. (UNVC) principles--treating the patient as whole and applying
“Total Wraparound” for patient, family and caregiver support.
Patrick Kelly, President of bioRemedies MD, LLC, remarked, “the time is now to bring these
products to the community weary from substance use disorders and barriers to mental health
treatment. This partnership with Univec, Inc. meets people where they are to help those
suffering from pain, opioid misuse, anxiety and sleep disorders.
Univec, Inc. will make private label and bioRemedies MD products available through several
distribution channels, including the recently acquired mental health centers. For additional
information about access to treatment
Univec Inc (UNVC)
Ford is roaring back to life and, according to CEO Jim Farley, the automaker is "just getting started."
Dividend coming back
Ford will also resume its dividend in the fourth quarter to shareholders of record on Nov. 19
Ford is also a backer, along with Amazon, of electric truck maker Rivian, which is planning to go public.
The stock has advanced over 92% this year, besting the S&P 500's 22% gain.
Ford Motor Company (F)
UNVC Univec (PK) Stock Price +27.1%
0.089 0.019 (27.1%)
UNVC
UNIVEC, Inc.
Common Stock
0.089
+27.14%
VOLUME
1,293,938
0.0823 / 0.089 (1 x 1)
Real-Time Best Bid & Ask: 05:00pm 09/29/2021
Delayed (15 Min) Trade Data: 03:37pm 09/29/2021
Pink
Pink Current Information
(UNVC)
The market for cough remedies globally generated $7.08 billion in 2020, and that figure is expected to reach $9.91 billion by 2030, according to Allied Global Research.
Algernon Pharmaceuticals will now pursue Ifenprodil in chronic cough based on encouraging recent study results in a Phase 2 trial.
https://www.streetwisereports.com/article/2021/09/29/biopharma-expands-clinical-program-of-lead-drug-candidate-to-treat-chronic-cough.html
Algernon Pharmaceuticals Inc. (AGNPF)
Wall Street’s Take On Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Stock.
https://stocksregister.com/2021/09/27/wall-streets-take-on-tonix-pharmaceuticals-holding-corp-nasdaq-tnxp-stock/
Tonix Pharmaceuticals Holding Corp (TNXP)
A stable solid philosophy which must be adhered to for the future of new and future billionaires.
Tesla, Inc. (TSLA
Elon Musk says Tesla Bot will be ready in a year. Can we believe him?
https://www.msn.com/en-us/news/technology/elon-musk-says-tesla-bot-will-be-ready-in-a-year-can-we-believe-him/ar-AANJXyn
https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=TSLA&insttype=&freq=2&show=&time=12
Tesla, Inc. (TSLA)
UNVC Security Details Univec Inc (PK) (UNVC)
Float
221,867,522
07/20/2021
52 Week High
+0.165
5 Year Chart
https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=UNVC&insttype=&freq=2&show=&time=12
About NMHA. The National Minority Health Association, founded in 1988 by Dr. David L. Dalton, Chairman, and CEO, UNIVEC
Press Release 8-23-2021
National Association for Home Care partners with National Minority Health Association to Mobilize and Vaccinate Home Health Workers in COVID-19 fight
AccentCare joins effort to kick off $11.1 million HHS grant to increase vaccination confidence and rates in underserved communities
OWINGS MILLS, Md., Aug. 23, 2021 /PRNewswire/ -- Increasing the vaccination rates among home health workers is critical to slowing the spread of COVID19. The National Association for Home Care & Hospice (NAHC) in consultation with industry leaders, estimate a vaccination range of 40 percent to 90 percent depending on the company and the discipline of the caregiver. With the rise of the Delta variant, NAHC is joining forces with the National Minority Health Association (NMHA) and the Flex for Checks program in a concerted effort to increase vaccinations among homecare workers.
National Association for Home Care & Hospice
National Association for Home Care & Hospice
The Flex for Checks (www.flexforchecks.org) community-based program was developed as part of an $11.1 million grant from the Health Resources and Services Administration (HRSA) that seeks to mobilize homecare workers to increase vaccination confidence and rates in underserved communities in the fight against COVID-19. The NMHA has also enlisted to support of television personality and author, Dr. Ian Smith, as a campaign spokesperson.
"We need to be honest and recognize our shortfall in vaccinations as an industry. But as an industry, we need to come together to solve it," said Bill Dombi, President and CEO, NAHC. "This is even more of an urgent issue as the Delta variant is quickly spreading among the unvaccinated, coupled with colder winter months approaching," Dombi continued. "We are pleased to join with NMHA in this collaborative effort."
AccentCare, a leading home care provider has agreed to join in the launch by introducing Flex for Checks to its employees with a goal of 5,000 shots. "We recognize that the industry has a problem when it comes to vaccinations," said Stephan Rodgers, Chief Executive Officer of AccentCare. "Vaccination is the first line of defense against COVID-19 and we want to be part of the solution, and that's why we are aggressively encouraging our team members to get vaccinated."
The HRSA grant is part of the approximately $125 million available through the U.S. Department of Health and Human Services (HHS) American Rescue Plan to develop and support a community-based workforce that will serve as trusted voices in sharing information about COVID-19 vaccines, increase vaccine confidence, and address barriers to vaccination for those living in vulnerable and medically underserved communities.
The grant funding will help community-based organizations like the NMHA better mobilize frontline home health workers as trusted messengers to conduct on-the-ground outreach to educate and assist individuals in receiving reliable information about vaccinations and reward health care agency workers for helping guide consumers to receive that vaccination as well as help increase vaccination among healthcare workers.
"We are thrilled to partner with NAHC and AccentCare as we seek to get as many home care workers and people in underserved areas vaccinated as possible," said Burgess Harrison executive director of the NMHA.
"Nothing like this program has been undertaken in this manner, where homecare agencies, workers, consumers, pharmacies, and software companies come together and flex their arms in the fight of our lives against COVID-19," continued Harrison.
About NMHA. The National Minority Health Association, founded in 1988 by Dr. David L. Dalton, Chairman, and CEO, UNIVEC Conglomerate, Inc. (UNVC), achieved its initial mission of ensuring the establishment of Offices of Minority Health in all 50 states. Today the NMHA is adding to its mission and deploying new programs that utilize patient-centered, value-based care, and new ways of enhancing care to patients where they are, lowering costs, and improving outcomes for minority and underserved communities. To find out more, visit www.theNMHA.org. Become a member of the NMHA Health Equity Action Leaders network (HEAL) and join the fight for health equity. https://www.thenmha.org/donation. Help build confidence in the vaccine www.GoFundMe.com/thenmha
About National Association for Home Care & Hospice (NAHC)
The National Association for Home Care & Hospice (NAHC) is the voice of home care and hospice. NAHC represents the nation's 33,000 home care and hospice providers, along with the more than two million nurses, therapists, and aides they employ. These caregivers provide vital services to Americans who are aged, disabled, and ill. Some 12 million patients depend on home care and hospice providers, who depend on NAHC for the best in advocacy, education, and information. NAHC is a nonprofit organization that helps its members maintain the highest standards of care. To learn more, visit nahc.org.
About AccentCare, Inc.
AccentCare, Inc. is a nationwide leader in post-acute healthcare, with innovative partnerships and care models covering the full continuum from personal, non-medical care to skilled nursing, rehabilitation, palliative care, hospice, and care management. Headquartered in Dallas, Texas, AccentCare has over 30,000 compassionate professionals in more than 250 locations, collectively serving over 200,000 individuals across 31 states. The company operates under regional brand names, including AccentCare, Alliance for Health, Gareda, Guardian, HRS, Seasons Hospice & Palliative Care, Sta-Home, Southeastern Health Care at Home, and Texas Home Health. AccentCare has over 60 strategic partnerships with insurance companies, physician groups, and major health systems, including joint venture companies branded as AccentCare Asante Home Health, AccentCare Fairview, AccentCare UCLA Health, AccentCare UC San Diego Health at Home, and Texas Home Health Group, an affiliation with Baylor Scott & White Health. Among its distinctions, AccentCare has a 4.5-star quality rating for legacy home health agencies, many of which have earned the HomeCare Elite distinction. All hospice and home health locations are CHAP- or Joint Commission-accredited, with designations from the We Honor Veterans program. The company's approach to care, including proprietary RightPath® disease-specific programs, leads the industry in avoidance of unplanned re-hospitalizations, faster starts of care, and quality performance. Learn more at accentcare.com.
This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $11.1million. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov.
For More Information
John Gonda
616-309-4888
jgonda@sage-growth.com
https://finance.yahoo.com/news/national-association-home-care-partners-130500679.html
https://www.prnewswire.com/news-releases/national-association-for-home-care-partners-with-national-minority-health-association-to-mobilize-and-vaccinate-home-health-workers-in-covid-19-fight-301360269.html
About NMHA. The National Minority Health Association, founded in 1988 by Dr. David L. Dalton, Chairman, and CEO, UNIVEC Conglomerate, Inc. (UNVC), achieved its initial mission of ensuring the establishment of Offices of Minority Health in all 50 states. Today the NMHA is adding to its mission and deploying new programs that utilize patient-centered, value-based care, and new ways of enhancing care to patients where they are, lowering costs, and improving outcomes for minority and underserved communities. To find out more, visit www.theNMHA.org. Become a member of the NMHA Health Equity Action Leaders network (HEAL) and join the fight for health equity. https://www.thenmha.org/donation. Help build confidence in the vaccine www.GoFundMe.com/thenmha
About National Association for Home Care & Hospice (NAHC)
The National Association for Home Care & Hospice (NAHC) is the voice of home care and hospice. NAHC represents the nation's 33,000 home care and hospice providers, along with the more than two million nurses, therapists, and aides they employ. These caregivers provide vital services to Americans who are aged, disabled, and ill. Some 12 million patients depend on home care and hospice providers, who depend on NAHC for the best in advocacy, education, and information. NAHC is a nonprofit organization that helps its members maintain the highest standards of care. To learn more, visit nahc.org.
About AccentCare, Inc.
AccentCare, Inc. is a nationwide leader in post-acute healthcare, with innovative partnerships and care models covering the full continuum from personal, non-medical care to skilled nursing, rehabilitation, palliative care, hospice, and care management. Headquartered in Dallas, Texas, AccentCare has over 30,000 compassionate professionals in more than 250 locations, collectively serving over 200,000 individuals across 31 states. The company operates under regional brand names, including AccentCare, Alliance for Health, Gareda, Guardian, HRS, Seasons Hospice & Palliative Care, Sta-Home, Southeastern Health Care at Home, and Texas Home Health. AccentCare has over 60 strategic partnerships with insurance companies, physician groups, and major health systems, including joint venture companies branded as AccentCare Asante Home Health, AccentCare Fairview, AccentCare UCLA Health, AccentCare UC San Diego Health at Home, and Texas Home Health Group, an affiliation with Baylor Scott & White Health. Among its distinctions, AccentCare has a 4.5-star quality rating for legacy home health agencies, many of which have earned the HomeCare Elite distinction. All hospice and home health locations are CHAP- or Joint Commission-accredited, with designations from the We Honor Veterans program. The company's approach to care, including proprietary RightPath® disease-specific programs, leads the industry in avoidance of unplanned re-hospitalizations, faster starts of care, and quality performance. Learn more at accentcare.com.
This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $11.1million. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov.
For More Information
John Gonda
616-309-4888
jgonda@sage-growth.com
SOURCE National Minority Health Association
Related Links
https://www.thenmha.org
Press Release | 08/16/2021
OTC Disclosure & News Service
UNIVEC,INC. ACQUISITION OF MENTAL HEALTH CLINICS Press Release | 08/16/2021
Univec,Inc Acquisition of Mental Health Clinics
Owings Mills, MD. August 16, 2021 - Univec, Inc. (OTCMarkets:UNVC) is pleased to announce the signing of a binding term sheet for the acquisition of accredited outpatient mental health centers in Maryland. These centers are community based centers which provide outpatient mental health counseling treatment for substance abuse and other ancillary services. The acquisition will add in excess of $17million in topline revenue to Univec and is expected to close on or around September 30, 2021 subject to final due diligence and valuation.
Dr. David Dalton, CEO of Univec, stated that "This is the beginning of Univec's business plan for "Wraparound Services" in the mental health and substance abuse environment. We are in the midst of a mental health and substance abuse pandemic and new ideas are needed to address the problem. Univec intends to be at the forefront of delivering targeted care in the mental health arena by treating multiple aspects of the issues."
Univec,Inc. (UNVC)
Univec,Inc. (UNVC) is an organization whose mission is to change the way healthcare is delivered in America. We are expanding solutions in the substance abuse arena for medication and to include mental and physical healthcare, telehealth services and technology systems and solutions. Univec treats the patient as a whole to improve outcomes for our patients and clients "Total Wraparound" is the foundation for patient support.
On behalf of the Board of Directors
Dr. David Dalton
https://www.otcmarkets.com/stock/UNVC/news/UNIVECINC-ACQUISITION-OF-MENTAL-HEALTH-CLINICS?id=316536
UNVC Security Details
Float
221,867,522
07/20/2021
08/24/2021 Quarterly Report - Amended Quarterly Report for the Period Ended on March 31, 2021 03/31/2021 A
08/24/2021 Annual Report - Amended Annual Report for the Period Ending on December 31, 2020 12/31/2020 A
08/11/2021 Attorney Letter with Respect to Current Information - Legal Opinion, Adequate Current Information and Disclosure for the Period Ended June 30, 2021 and related disclosures 06/30/2021 A
08/11/2021 Quarterly Report - Quarterly Report 06/30/2021 A
08/11/2021 Quarterly Report - Quarterly Report for the Period Ended on June 30, 2021 06/30/2021 A
08/05/2021 Attorney Letter with Respect to Current Information - Legal Opinion, Adequate Current Information and Disclosure for the Amended Period Ended December 31, 2019, December 31, 2020 and March 31, 2021 and related disclosures 03/31/2021 A
https://www.otcmarkets.com/stock/UNVC/disclosure
Videos
This company has not added any videos yet
Univec expected on or around September 30, 2021
Filings and Disclosure
Quarterly Report - Amended Quarterly Report for the Period Ended on March 31, 202108/24/2021
Annual Report - Amended Annual Report for the Period Ending on December 31, 202008/24/2021
Attorney Letter with Respect to Current Information - Legal Opinion, Adequate Current Information and Disclosure for the Period Ended June 30, 2021 and related disclosures08/11/2021
Univec Inc (UNVC)
2022 Ford Bronco's new Eruption Green paint looks incredible
As pandemic rages on, Ford's not alone in delaying return to office
In the latest signal that the COVID-19 pandemic is permanently transforming workplaces, Ford Motor Co. on Wednesday announced it is once again delaying its return-to-office date and introducing yet another remote work option to provide greater flexibility to salaried employees.
The automaker informed white-collar employees in North America, South America and most of its International Market Groups whose jobs are not dependent on being on-site that they should not expect to return to offices until at least January. Employees were sent home in March 2020 and most recently were slated to return in October.
https://eu.detroitnews.com/story/business/autos/ford/2021/08/26/ford-other-metro-detroit-employers-delay-returning-office/5591425001/
2022 Ford Bronco's new Eruption Green paint looks incredible
https://www.msn.com/en-us/autos/news/2022-ford-bronco-s-new-eruption-green-paint-looks-incredible/ar-AANDySc
Ford Motor Company (F)
Continental Stock Transfer & Trust Company
Transfer Agent
1 State Street Plaza
30th Floor
New York, NY 10004
212-509-4000
Transfer Agent Verified
Donald R. Keer, P.E., Esq
Attorney Letter
http://www.otcmarkets.com/financialReportViewer?symbol=UNVC&id=292244
3663 Greenwood Circle Chalfont Pennsylvania 18914
Donald R. Keer, P.E., Esq
July 21, 2021
OTC Markets Group, Inc.
304 Hudson Street, 3rd Floor
New York, NY 10013
RE: Legal Opinion, Adequate Current Information and Disclosure
Filing by Univec, Inc. (UNVC) Quarter Report for the Period Ended March 13, 2021 and related disclosures
The Issuer's transfer agent is:
Continental Stock Transfer & Trust Company
(212) 509-4000
1 State Street
30th Floor
New York, NY 10004-1561
Counsel confirmed that the transfer agent is registered with the SEC via the official SEC website and
3663 Greenwood Circle Chalfont Pennsylvania 18914
215-962-9378
Donald R. Keer, P.E., Esq
Filings and Disclosure
OTC Disclosure & News
Active
All
Publish Date
Title
Period End Date
Status
07/21/2021 Attorney Letter with Respect to Current Information - Univec, Inc - Opinion Letter Adequate Current Information Annual Report ended on December 31, 2020 12/31/2020 A
07/21/2021 Attorney Letter with Respect to Current Information - Univec, Inc - Opinion Letter Adequate Current Information Annual Report ended on December 31, 2019 12/31/2018 A
07/21/2021 Attorney Letter with Respect to Current Information - Univec, Inc - Opinion Letter Adequate Current Information Quarterly Report ended on March 31, 2021 03/31/2021 A
07/21/2021 Annual Report - Univec, Inc - Annual Report for the Period Ended on December 31, 2020 12/31/2020 A
07/21/2021 Annual Report - Univec Inc. - Annual Report for the Period Ended on December 31, 2019 12/31/2018 A
07/21/2021 Quarterly Report - Univec Inc - Quarterly Report for the Period Ended on March 31, 2021 03/31/2021 A
07/27/2011 Quarterly Report - corrected 06/30/2011 A
https://www.otcmarkets.com/stock/UNVC/news
Univec (UNVC)
52week 273.00 - 900.3999
Tesla, Inc. (TSLA)
Tonix Pharmaceuticals Holding Corp., whose market valuation is $324.67 million at the time of this writing, is expected to release its quarterly earnings report Aug 09, 2021 – Aug 13, 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.06 per share this quarter, however they have predicted annual earnings per share of -$0.26 for 2021 and -$0.2 for 2022. It means analysts are expecting annual earnings per share growth of 52.70% this year and 23.10% next year.
https://stocksregister.com/2021/07/20/tonix-pharmaceuticals-holding-corp-nasdaq-tnxp-hidden-gems-in-a-time-of-volatility/
Tonix Pharmaceuticals Holding Corp (TNXP)
Recent Updates Univec Conglomerate Inc (UNVC)
Updated the new web site is live: univechealth.com
New TA Continental Stock Transfer & Trust Company is confirmed
Univec name changed to Univec Conglomerate Inc confirmed
Filings getting done per Chief Executive Officer
Market Cap Market Cap 235,878,935 Updated 06/24/2021
Ifah video starring Dr. David Dalton https://tinyurl.com/IfahrecapUNVC5dollarsplus
Ifah recap has been graciously documented and shared by one of our a fellow investors:
-UNVC has clinics to help people and most services are free of charge
-They receive money from medicare and Medicaid.
-We believe you have to have a total wraparound program
-If they come out of prison, they do not have homes, we help them with that
-We help people transition from prison or streets
-We provide the services, that’s how we make the revenue
-You have to give them financial education
-My son in law runs a non profit called operation hope
-There one focus is to have financial education for individuals that do not even know how to operate a checking account
-When they go into our temporary housing they go into our financial education program
-There is a company we partner with, one of the owners is the owner of the Atalanta Hawks
-Tony Ressler and Aries Capital and my son in law under promise homes, provide permanent homes
-We give them temporary homes, permanent homes, financial education, total wraparound services
-UNIVEC health telehealth we use to partner with a company called Teladoc
-Teladocs platform is not specific to the platform we needed
-So we started our own platform, so we can meet the patient where they are
-In telehealth you cannot give the patient a complicated system
-It should be as simple as opening the phone and clicking a button
-Univec gives them the phone free of charge
-In line with our telehealth programs, we address mental health, cardio, diabetes and asthma, as our 4 primary support systems and we also tie it into products
-The cannabis CBD platform, we have done studies with University of Maryland and bioremedies to make sure what is being put out there is the most efficacy CBD and thc that in fact can address some of the problems as relates to pain management
-Were looking at the transdermal delivery pathway, we believe transdermal pathway is the pathway to go
-We partnered with companies such as Amazon, just to name a small one
-Amazon looks at things in a different way, but they still need to be educated on how the fact reimbursement is made
-Amazon will be making an announcement that they will provide 6 months of medication to their patients home
-We are in new era of health care
More to come
Univec Conglomerate Inc (UNVC)
US Postal Service delivery trucks to have Ford engines, transmissions in new fleet
https://www.msn.com/en-us/money/companies/us-postal-service-delivery-trucks-to-have-ford-engines-transmissions-in-new-fleet/ar-AALmzON
Ford Motor Company (F)
Tonix Pharmaceuticals to Present at Raymond James Human Health Innovation Conference
https://ca.finance.yahoo.com/news/tonix-pharmaceuticals-present-raymond-james-110000550.html
Tonix Pharmaceuticals Holding Corp (TNXP)
EV Cp Cramer says buy ford
https://www.thestreet.com/investing/electric-vehicle-checkpoint-jim-cramer-says-to-buy-ford
Ford Motor Company (F)
The National Minority Health Association (NMHA) organization founded in 1988 by "Dr. David L. Dalton", Chairman and CEO of UNIVEC Conglomerate Inc. (UNVC).
About NMHA
The organization achieved its initial mission of ensuring the establishment of Offices of Minority Health in all 50 states. Today the NMHA is deploying Operation Healthy You™ (OHY), a program that identifies areas of healthcare disparity and works with healthcare providers and community resources to address identified needs. The program is intended to lower the long-term overall cost of healthcare and improve outcomes for minority and underserved communities.
Meet the NMHA Board
DR. DAVID DALTON
CHAIRMAN, BOARD OF DIRECTORS
Dr. David Dalton is the first black pharmaceutical executive in the chain drug industry. Honored as one of the top ten graduates over 100 years. In Four Halls of Fame, Senatorial Medal of Freedom and Veteran. He served in several capacities with Rite Aid Corporation including Corporate Vice President. He left Rite Aid Corporation to acquire Peoples Drug Stores with an investment group inclusive of Robert Bass of Texas. Dr. Dalton served as Senior Vice President. He founded Managed Care Rx merged it with Bergen Brunswick, a drug wholesale company sales over 14 billion. Health Resources, Inc. for which he is Founder, President and CEO is a national PBM and Pharmacy Services, Inc. a prescription mail service company. Health Resources Inc. has been recognized in Black Enterprise Magazine top 100 for over 25 years. Dr. Dalton is President and CEO of Univec Conglomerate Inc. a public company that manufactures and distributes specialty pharmaceuticals and cannabis CBD. Physician and Pharmaceutical Services Inc, (PPSI) is the pharmacy sample services division of Univec Conglomerate Inc. He is Executive Chairman of Wellness TeleMed(Telemedicine) and WellnessRx (Mental Health and Substance abuse clinics)
Dr. Dalton is one of the original members and directors of the National Council of Prescription Drug Programs (NCPDP). Founder of National Minority Health Association. He has received national and local recognition by the President and Senate of the United States and Congressional Black Caucus. The University of West Virginia recognized him as a Distinguished Alumni and again honored him as Outstanding Alumni of West Virginia School of Pharmacy and Outstanding Service recognition to the School of Pharmacy. Dr. Dalton was inducted into the Black CEO Hall of Fame in 2006. Honored by his hometown of Grafton, West Virginia as the author of city slogan Grafton, West Virginia “ The City where Mother’s Day Began “ He was inducted into the Taylor County School's Hall of Fame in 2013. He was inducted into the West Virginia University School of Pharmacy Centennial Hall of Fame in 2014 and Selected "Top 100 Healthcare Leaders Worldwide " by IFAH 2019
Dr David Dalton
HAROLD YOUNG, ESQ
VICE CHAIRMAN, BOARD OF DIRECTORS
Harold D. Young, Esq, has over thirty years of experience representing persons in various legal disciplines. His practice areas include wills and estates, probate, family law, elder law, real estate, small business, corporations, government, housing, and personal injury. Harold is admitted to practice in all courts in Maryland and the United States District Court. Harold’s legal practice has a special emphasis on preserving the assets of senior and disabled members of the community.
For over thirty-five years, Young has worked in communities throughout Maryland on housing and community development issues, bringing opportunities to communities and people. As Director of the U.S. Department of Housing and Urban Development, Harold was responsible for the delivery of national programs of the U.S. Department of Housing and Urban Development. He was the single point of contact for all of the Department’s efforts in the state and led a staff of highly trained and qualified housing and community development professionals available to communities, non-profit organizations, businesses, government officials, and citizens for consultation on areas as diverse as rural development, Brownfields, outreach, and community planning.
Harold coordinated housing resources for the improvement of local communities, advised the Secretary of HUD, assistant secretaries, and other senior departmental officials on specific housing and community development needs, convened community leaders, housing professionals, non-profit organizations, and elected officials to address important housing and community development issues. He was HUD’s spokesperson in Maryland for housing policy related to public and assisted housing, fair housing, and community-based initiatives. He led a staff of 100 plus employees who work in Fair Housing and Equal Opportunity, Public Housing, Single Family Housing, Multi-Family Housing, and Community Planning and Development.
A graduate of the University of Baltimore School of Law and a member of the Maryland State Bar Association, Harold also holds a Bachelor of Arts degree in Economics from Virginia State University and a Master of Arts in Urban Planning and Policy Analysis from Morgan State University. A consummate professional, dedicated community activist, and exceptional administrator, he has been an advisor to numerous faith-based organizations, nonprofit organizations, and public officials. Harold served as an adjunct professor and guest lecturer at Morgan State University. Harold currently practices law, concentrating in probate, estates and trusts, torts, administrative, business, and corporate law.
AWARDS:
HUD Secretary’s Fair Housing Award
HUD Secretary’s Customer Service Award
Real Estate Brokers of Baltimore, Inc., Democracy in Housing Award
The Baltimore Marketing Association, Inc., Harold D. Young, Esquire, Leadership Award
Harold Young, Es
COL. JAMES WILLIAMS (RET)
BOARD MEMBER
Col. James Williams, a prostate cancer survivor since 1991, Jim is the principal of Jim Williams, and Associates, Camp Hill, PA - a consulting firm specializing in human resources management, prostate cancer awareness, education, and advocacy. Before launching Jim Williams and Associates, Jim was the Operations Manager, Human Resources, Penn State Geisinger Health System – The Milton S. Hershey Medical Center, Hershey, PA. Other professional experiences include Director, Human Resources, American Bar Association at their headquarters in Chicago, IL, and as a Corporate Personnel Manager, Montgomery Ward and Company, Inc. at their headquarters in Chicago. He retired from the United States Regular Army as a full colonel before joining Montgomery Ward.
AFFILIATIONS:
Chairman, Board of Directors, Pennsylvania Prostate Cancer Coalition (PPCC), Harrisburg, PA
• Life member, Alpha Phi Alpha Fraternity, Inc, Baltimore, MD
• Life member, NAACP, Baltimore, MD
• Life member, The Retired Officers Association, Washington, DC
• Life member, West Chester University Alumni Association, West Chester, PA
• Member Advisory Board, Prostate Cancer Choice Research Project, Mayo Clinic
• Member, Alpha Phi Alpha Fraternity (Zeta Theta Lambda), Harrisburg, PA
• Member, Community Advisory Board, Urology of Central PA (UCPA), Camp Hill PA
• Member, Editorial Board, Cancer Today magazine, American Association for Cancer Research (AACR), Phila PA
• Member, Tm #1 Admission Committee, Penn State College of Medicine, Hershey PA
• Past Chair, Intercultural Cancer Council (ICC), Houston, TX
• Vice President, Beta Pi Boule, Inc., Sigma Pi Phi Fraternity, Harrisburg, PA
• Vice President, Intercultural Cancer Council Caucus (ICCC), Larkspur, CA
The recipient of dozens of awards for his many works, Col. Williams has authored multiple publications as has received accreditation as an SPHR - Senior Professional in Human Resources from the Society for Human Resources Management (SHRM) and is an instrument-rated private pilot
Col. Williams received his Master of Science in Education from Siena College, Loudonville, New York, and his Bachelor of Science in Education from West Chester University, West Chester, Pennsylvania.
Col James Williams, (Ret)
R. ROBERT A. SCOTT
BOARD MEMBER
Dr. Robert A Scott is a Professor Emeritus, Pennsylvania State University. He is currently the administrator of R. Scott Associates. This is an organization that conducts research and provides training and consultation in Organizational Strategic Planning, Organizational Inclusion and Diversity Management, Human Relations in the New Millennium, and Motivation and Achievement Theory and Practice.
Dr. Scott is a native of Reading Pennsylvania, a Marine veteran, a graduate OF A&T University with a degree in Sociology, a graduate of Atlanta University, and a Ph.D. from Pennsylvania State University. Additionally, he attended advanced courses in Industrial Relations and Achievement Motivation at Harvard University and Cornell University
Employment includes Veterans Administration Hospital as a psychiatric counselor, the New York Correctional System as a diagnostician, and with the Youth House for Youth, and Pennsylvania State University School of Medicine.
Dr. Scott’s major research, teaching, training, and consultation concentration include Individual and Organizational Dynamics that Influence Effective and/or Productive Interactions. He and his colleagues have designed and distributed training curricula that are used nationally and internationally. Their work has influenced policies and practices in private, public, and federal organizations. A major focus, more recently, is on the issues specific to ethnic disparities in health-care treatment and organizational diversity.
Dr. Scott’s interest and motivation in both civil and human rights stem from his parents, who were very active in the integration of churches in Reading, Pennsylvania. His brother, who was inducted into the Jazz Hall of Fame, was instrumental in integrating the United States Army Band. Dr. Scott continued to demonstrate his passion and commitment to Human Rights with participation in the struggle for equity as a marine, as a college student, and as a college professor. As president of the student body at Atlanta University, he helped to engineer civil rights demonstrations and programs, with the guidance of Dr. M.L. King. At Pennsylvania State University, in addition to his research and teaching, he served as faculty advisor for minority students, staff, and faculty. He was very active in recruitment and mentoring.
Awards: Penn State University Professor of the Year Award, Cornelius Community Service Award, Keystone Outstanding Citizen Award, Diversity Champion Award, Outstanding African-American Men Legacy Award, and the 2009 Civil Rights Unsung Hero Award He serves on numerous boards and committees, including, co-chair of Pennsylvania’s veteran’s committee to elect President Barack Obama.
Dr Robert Scott
DENISE PINES
BOARD MEMBER
Immediate Past President, California Medical Board
Denise Pines is an experienced senior leader with a demonstrated history of working in the medical practice industry. Skilled in Nonprofit Organizations, Government, Sales, Entrepreneurship, and Event Management. Denise is a strong business development professional with a Master of Business Administration focused in International Business from John F. Kennedy University.
Denise is the immediate past President of the Medical Board of California, co-author of FemAging: HealthTech Report (www.femaging.com ) and Founder of the new Wise Pause Lifestyle summit (https://wisepause.com ), Executive producer of the award-winning film, “PUSHOUT: The Criminalization of Black Girls in School” ( https://pushoutfilm.com/team ) an example of her stellar career of producing informative and empowering events and media programs.
Denise rallied a team of the finest experts in the business to share with women a plethora of ways to combat and manage the myriad of changes that can occur in the female body as a result of the often-dreaded menopause and perimenopause.
Denise is also the Co-Founder of “Hot Flash Tea” by Tea Botanics ( http://www.teabotanics.com). It’s a custom brand of teas for hormonal balance and wellness, and that menopause doesn’t need to be a time of endless suffering for women.
Along with the National Minority Health Association, Denise sits on the Martin Luther King Community Hospital Foundation board and serves in leadership positions in the California University of Science and Medicine (CUSM) School of Medicine, the Triple Step Toward the Cure, and the Taiwan Tea Manufacturers Association.
Dr Robert Scott
DR. ERIC RITTER
BOARD MEMBER
Dr. Eric Ritter was born and raised in Washington DC. He attended undergraduate school at Brandeis University and majored in psychology with a pre-medical and education core. Dr. Ritter received his masters degree in education and principal certification from Harvard University. He earned his medical degree from Meharry Medical College in Nashville Tennessee. His internal medicine residency was at Boston Medical Center and Franklin Square, Hospital Center. After graduating from residency program he has worked as a hospitalist in the inpatient setting for nine years. At the present time, he specializes in addiction medicine and owns his own addiction medicine company and works as an impatient detoxification doctor. Dr. Ritter also serves as a certified ringside physician on the professional and amateur level. In hIs free time Dr. Ritter enjoys church, raising his three daughters, boxing, and service to his community.
Dr Robert Scott
BURGESS HARRISON, MBA
EXECUTIVE DIRECTOR & BOARD MEMBER
Burgess Harrison., MBA Burgess brings a wide breadth of expertise to the National Minority Health Association. He comes with more than 25 years of home health, homecare, electronic visit verification, and telehealth technology experience. He is a pioneer in electronic visit verification and possesses a unique understanding of the market and issues patients and providers face. Burgess is an educator, former adjunct professor, marketing executive, and software business founder who happens to be a unique perspective to minority health. As an Albino with low vision from two black parents, Burgess leads the association with a unique personal healthcare journey and understands the impact of the lack of access as a child, as well as being an experiment or “lab project” for healthcare professionals.
He is the co-founder of Statchek, Inc.a pioneer in electronic visit verification in-home care (acquired by Wipro NYSE: WIT) and Ankota LLC, a SaaS home care technology company.
Having a family that has received home care and assisted living as well as elderly relatives afflicted with PICKs and dementia, Burgess is acutely aware of the issues that face minority and disadvantaged Americans when they need simple and complex medical services.
Burgess has developed innovative and forward-thinking programs to non-profits as he served on the boards of the American Red Cross of South Central Connecticut and Shoreline Foundation (S.A.R.A.H.). This is Burgess’s passion. He developed the concept for Operation Healthy You and after a year of development, Dr. Dalton saw the potential and joined forces to bring it to life in the NMHA. To borrow a phrase from his good friend and mentor John Hope Bryant, let’s go!
Burgess Harrison
DAVID COLE, CMP
PROGRAM DIRECTOR
BOARD MEMBER
David Cole is an accomplished healthcare professional and business executive with 20+ years of experience building multiple successful products and companies. He is an expert in SaaS product development, marketing, sales, and complex retail channel development. A skilled strategist and business development specialist, David has extensive experience working with non-profit organizations, government agencies, regulatory authorities, health care systems, and providers.
David co-founded Statchek, Inc., a pioneer in electronic visit verification, which was acquired by what is now Wipro (NYSE-WIT). David also served as the first vice president of technology for AccentCare, Inc. and subsequently co-founded two non-medical home care agencies and served as the executive director for Interim Home Health in Atlanta, GA, a Medicare-certified skilled home health agency. David is a principal of MRI First, a low-cost provider of MRI imaging services, where he currently serves as a director. David also developed CareMaestro, a system that reduced readmissions for a large west-coast hospital chain by more than 80%.
David is a certified Chronic Care Professional (CCP), and a California certified administrator for Residential Care Facilities for the Elderly (RCFE). He is also a former Medicare administrator, and a Certified Memory Impairment Specialist-Instructor (CMIS-I).
Univec Conglomerate Inc. (UNVC)
https://www.thenmha.org/
Jim Cramer Says Take a Hard Look and Buy Ford Stock
https://www.thestreet.com/video/jim-cramer-take-hard-look-ford
Ford Motor Company (F)
Recent Press Release Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions
https://ir.tonixpharma.com/press-releases/detail/1245/tonix-pharmaceuticals-announces-publication-of-patent
Tonix Pharmaceuticals Holding Corp (TNXP)
Algernon Highlights New Independent Research Review Identifying Ifenprodil as a Potential COVID-19 Treatment
Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company, is pleased to highlight an independent research review published in the January 5 th edition of the European Archives of Psychiatry and Clinical Neuroscience that identified Ifenprodil as a possible re-purposed drug candidate for the treatment of COVID-19. The Review focuses on the sigma-1 receptor in the endoplasmic reticulum
Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to highlight an independent research review (the “Review”) published in the January 5 th edition of the European Archives of Psychiatry and Clinical Neuroscience that identified Ifenprodil as a possible re-purposed drug candidate for the treatment of COVID-19.
The Review focuses on the sigma-1 receptor in the endoplasmic reticulum, a network of membranes inside a cell through which proteins and other molecules move, and its important role in SARS-CoV-2 replication in cells. The Review proposes the repurposing of traditional central nervous system (CNS) drugs that have a high affinity at the sigma-1 receptor, naming Ifenprodil as a potential treatment of SARS-CoV-2-infected patients.
The Review can be found here at Sigma-1 Receptor Research and was authored by Kenji Hashimoto and supported in part by the Japan Society for the Promotion of Science and the Japan Agency for Medical Research and Development.
The Company recently announced that the last patient from the Phase 2b part of its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19, completed treatment as well as the required two-week follow up. The Company is projecting the final data set will be available before the end of February 2021.
“To date, we have mostly focused on Ifenprodil’s role as an NMDA receptor antagonist when exploring its potential as a COVID-19 therapeutic,” said Dr. Mark Williams, CSO of Algernon Pharmaceuticals. “However, its role as a sigma-1 receptor agonist is also well established and the connection with this receptor being a key therapeutic target involving SARS-CoV-2 replication is a very promising discovery, and adds to our confidence as we wait for the final results from our COVID-19 Ifenprodil study.”
The Company advises that it is not making any express or implied claims that Ifenprodil has the ability to eliminate, cure or contain COVID-19 (or the SARS-2 Coronavirus) at this time.
About NP-120 (Ifenprodil)
Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B). Ifenprodil prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils. Ifenprodil also exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress.
The Company believes Ifenprodil may be able to reduce the infiltration of neutrophils and T-cells into the lungs where they can release glutamate and cytokines respectively. The latter can result in the highly problematic cytokine storm that contributes to the loss of lung function and ultimately death as has been reported in COVID-19 infected patients.
About Algernon Pharmaceuticals Inc.
Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
https://investingnews.com/news/biotech-investing/algernon-highlights-new-independent-research-review-identifying-ifenprodil-as-a-potential-covid-19-treatment/
Algernon Pharmaceuticals Inc. (AGNPF)
Tonix Pharmaceuticals Holdings Corp. Prices $40M Common Stock Offering Priced at-the-Market Under Nasdaq Rules
https://www.nasdaq.com/press-release/tonix-pharmaceuticals-holdings-corp.-prices-%2440m-common-stock-offering-priced-at-the
Tonix Pharmaceuticals Holding Corp (TNXP)
Here's Why Rite Aid (RAD) Marching Ahead of the Industry
Zacks Rank #2 (Buy)
FEATURED IN SMART INVESTING
Learn More
Rite Aid Corporation RAD has been benefiting from strength in Elixir, rise in pharmacy sales and robust online performance. Driven by this, the company reported impressive third-quarter fiscal 2021 results. Also, solid performance in the Retail Pharmacy and Pharmacy Services segments acted as upsides. As a result, management updated its guidance for fiscal 2021, which seems encouraging.
Notably, shares of this Zacks Rank #2 (Buy) stock has surged 70.5% in the past three months compared with the industry’s growth of 23.5% and against the Retail-Wholesale sector’s decline of 2.5%.
That said, let’s delve into the factors that make Rite Aid a promising bet
Factors Narrating Rite Aid’s Growth Story
Given the COVID-19 situation, Rite Aid has been instrumental in serving the society through its products, delivery facilities and several testing sites. Since the onset of the pandemic, the company has been providing home delivery services to customers with an eligible prescription, with the benefit of zero delivery fees.
Also, pick up services for prescriptions and over-the-counter products as well as the drive-through option at more than 50% of its retail locations are in place. Moreover, it has launched the Buy Online Pickup In Store initiative in a bid to offer better drive-through and curbside pickup options.
Apart from these, the company expanded the Instacart delivery facility and received positive feedback for the same. Driven by these efforts, online revenues skyrocketed 225% year over year in the fiscal third quarter on the back of a revamped website and mobile app.
Earlier, the company partnered with ScriptDrop to expedite the prescription delivery process. This facility is being rolled out in a phased manner and will be completed by the end of fiscal 2021. Also, the launch of Rite Aid Virtual Care, driven by strong demand for Tele Health, bodes well.
Moving on, it has already reached the milestone of 1 million COVID-19 tests in partnership with the U.S. Department of Health and Human Services. Rite Aid is joining forces with the CDC to distribute vaccines for the second phase of the rollout.
Further, Rite Aid remains focused on strengthening its foothold in mid-market PBM, innovating across its retail and mail-order pharmacy channels, enhancing the in-store experience by curated digital offerings, improving merchandises and rebranding its image with a new logo. Keeping in these lines, the company revamped more than 700 stores and is likely to complete the rest in 2021. It also launched its first three Stores of the Future and intends to open more in the fiscal fourth quarter.
https://www.nasdaq.com/articles/heres-why-rite-aid-rad-marching-ahead-of-the-industry-2021-01-11
Rite Aid (RAD)
Tonix Pharmaceuticals to Participate in Upcoming January Conferences
https://www.tonixpharma.com/news-events/press-releases/detail/1242/tonix-pharmaceuticals-to-participate-in-upcoming-january
CHATHAM, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present at four upcoming virtual conferences in January.
Event H.C. Wainwright BioConnect Conference
Date January 11-14, 2021
Time Presentation available on demand January 11-14, 2021
Event Biotech Showcase 2021
Date January 11-15, 2021
Time Presentation available on demand January 11-15, 2021
Event Sidoti Winter Virtual Investor Conference
Date Wednesday, January 13, 2021
Time 9:15 a.m. ET
Event ICR Conference 2021
Date Thursday, January 14, 2021
Time 9:15 a.m. ET
Webcasts of the H.C. Wainwright, Sidoti and ICR conferences presentations will be available under the IR Events tab of the Investors section of the Tonix website at www.tonixpharma.com.
About Tonix Pharmaceuticals Holding Corp.
Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL*, is in mid-Phase 3 development for the management of fibromyalgia since positive data on the RELIEF Phase 3 trial were recently reported. The Company expects topline data in the Phase 3 RALLY study in the fourth quarter of 2021. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases. Tonix’s lead vaccine candidate, TNX-1800**, is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix expects efficacy data from animal studies of TNX-1800 in the first quarter of 2021. TNX-801**, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox.
*TNX-102 SL is an investigational new drug and has not been approved for any indication.
**TNX-1800 and TNX-801 are investigational new biologics and have not been approved for any indication.
This press release and further information about Tonix can be found at www.tonixpharma.com.
Tonix Pharmaceuticals Holding Corp (TNXP)
Tonix Pharmaceuticals and Massachusetts General Hospital (MGH) Enter into Research Collaboration on Tonix’s Third Generation anti-CD40-Ligand Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Kidney Transplant Rejection
https://www.tonixpharma.com/news-events/press-releases/detail/1241/tonix-pharmaceuticals-and-massachusetts-general-hospital
Tonix Pharmaceuticals Holding Corp.
Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL*, is in mid-Phase 3 development for the management of fibromyalgia since positive data on the RELIEF Phase 3 trial were recently reported. The Company expects topline data in the Phase 3 RALLY study in the fourth quarter of 2021. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases. Tonix’s lead vaccine candidate, TNX-1800**, is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix expects efficacy data from animal studies of TNX-1800 in the first quarter of 2021. TNX-801**, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox.
Tonix Pharmaceuticals Holding Corp (TNXP)
Study of the treatment of COVID-19, has now completed treatment as well as the required two-week follow up.
The Company announced positive trending interim data for the Phase 2b part of it Phase 2b/3 Ifenprodil COVID-19 Study, on December 15, 2020. The Company is projecting the final data set will be available before the end of February
Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.
https://apnews.com/press-release/globe-newswire/business-corporate-news-drug-trials-products-and-services-health-care-industry-399a7d3b15ccf04e798ead8d65238a47
Algernon Pharmaceuticals Inc. (AGNPF)
Investor Presentation NASDAQ:TNXP
TNX-18001: a COVID-19 Vaccine Candidate
• Utilizes Tonix’s proprietary horsepox virus as a vector
• Encodes a protein from SARS-CoV-2, the cause of COVID-19
• Developed in collaboration with University of Alberta, Canada
COVID-19 Vaccine Landscape
• We expect more than one vaccine will be approved by FDA
• Different vaccines for different individuals
• More than 150 vaccines in development
• Diversity of approaches is important since protective immunity is not yet
understood
• Technologies range from never tested before to 220 years old
• Uncertainty exists around efficacy, durability and importantly, safety
• Live attenuated vector systems in development include:
• Tonix (horsepox), Tonix (bovine parainfluenza), Merck (measles1- and VSV2-
based), Zydus Cadila (measles-based)
• Long term, durable immunity
• Expected to stimulate T cells and provide years to decades of
protection
• Single administration, scalable manufacturing
• Low dose is amplified by replication, mRNA and protein synthesis at
vaccination site
https://content.equisolve.net/tonixpharma/media/cfe6777f777cbb421861e6b7727ebb85.pdf
Tonix Pharmaceuticals Holding Corp (TNXP)
Must Read: Operational & Balance Sheet Improvements
December 16, 2020
Aurora Cannabis Announces Operational & Balance Sheet Improvements
Aurora Cannabis Announces Operational & Balance Sheet Improvements
Revised Credit Facility Terms Supports Execution of Business Transformation Plan that Focuses on Long-Term, Sustainable Revenue Growth & Improving Operating Cashflow
Credit facility terms improved including maturity extension to December 2022
~$450 million of cash on balance sheet & improving cashflow positions company to drive sustainable, long-term revenue growth
Production volumes now aligned to sales by adopting a more agile, variable cost model
Expects fiscal 2021 Q2 Adjusted EBITDA loss to improve from Q1 despite a resurgence of Covid-19 restrictions in key markets
NYSE | TSX: ACB
EDMONTON, AB, Dec. 16, 2020 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today provided a business update.
"Our substantial liquidity position has enabled us to revise our credit facility terms by extending maturity and transitioning us from a minimum EBITDA covenant to a minimum liquidity covenant, thereby providing us with the financial flexibility we need to execute our business transformation plan. We are already seeing progress with improving cashflow and product successes such as the recent relaunch of our vapour portfolio. We are also driving our consumer strategy that will serve as a foundation for sustainable revenue growth and profitability over the long-term" stated Miguel Martin, Chief Executive Officer of Aurora.
"We are moving to a more variable cost structure in cultivation by expanding our network of external supply and responsibly scaling back production from our fixed asset network. Specifically, in November we closed our Aurora Sun facility and are now scaling back production at Aurora Sky to 25% of its previous capacity. At this level of production, we intend to transform the Sky facility into a high-value cultivation center for our premium strains, and in turn, better align production with current demand for premium flower."
"Our plan to address the opportunities in the Canadian consumer market, combined with a formidable balance sheet, positions Aurora to remain the leader by revenue in the high-margin Canadian medical market. It also allows the Company to invest in the international medical business, which is exhibiting solid growth. Lastly, we will be able to build on our CBD brand Reliva, which is #1 ranked by Nielsen in U.S. CBD."
Press Releases
https://investor.auroramj.com/news-and-events/press-releases/
Mr. Martin concluded "These hard decisions are being taken to improve cashflow and provide agility to our business. We will continue to make decisions and transform Aurora in the long-term best interests of our shareholders. We look forward to 2021 and providing updates on our business transformation."
About Aurora
Aurora is a global leader in the cannabis industry serving both the medical and consumer markets. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis dedicated to helping people improve their lives. The Company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, and Reliva CBD. Providing customers with innovative, high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, performance, wellness and recreational markets wherever they are launched. For more information, please visit our website at www.auroramj.com.
Aurora's common shares trade on the TSX and NYSE under the symbol "ACB", and is a constituent of the S&P/TSX Composite Index.
Aurora Cannabis Inc. (ACB)
Major competitors for Tesla include traditional auto companies such as:
Ford Motor Company (F), the multinational automobile manufacturer founded in 1903.3?
General Motors (GM), the U.S.-based automobile manufacturer founded in 1908.4?
Honda Motor Company (HMC), a multinational automobile manufacturer founded in 1948.5?
Navistar (NAV), commercial vehicle holding company.
Oshkosh (OSK), truck and military vehicle manufacturer, founded in 1917.6?
PACCAR, truck manufacturer.
Spartan Motors, a specialty chassis and vehicle manufacturer.
Tata Motors, the largest automotive manufacturer in India.
Toyota Motor Corp. (TM), a multinational automotive manufacturer.
Wabco (WBC), manufacturer of systems for heavy-duty commercial vehicles.
Tesla is doing fantastic and I will continue investing in TSLA along with some other competitors such as Ford at a lower pps. Ford has been noted as a confirmed competitor, however Tesla with Elon Musk at the helm will continue to amaze the world.
Tesla, Inc. (TSLA)